KalVista Pharmaceuticals Overview
Valuation check: KALV's ROE is 4539.43%, above the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow4539.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
KalVista Pharmaceuticals (KALV) currently reports a ROE of 4539.43%. That is above the Healthcare sector average of 21.28%. Use the charts on this page to explore KalVista Pharmaceuticals's ROE history and peer comparisons.
KalVista Pharmaceuticals's ROE of 4539.43% is higher than the Healthcare sector average of 21.28%. That is roughly 21232.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but KalVista Pharmaceuticals's current 4539.43% should be judged against Healthcare norms (sector average: 21.28%) and against KALV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 4539.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for KalVista Pharmaceuticals, and consider following KALV for alerts when major investors trade the stock.
KalVista Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 4539.43% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KALV with unrelated industries.
